AXONYX - Alzheimer Blockbuster in Entwicklung?!! - 500 Beiträge pro Seite

[ollinbg]

Axonyx Inc. (AXYX)

Aus den News von gestern:
"This is the first time that a treatment for AD is being studied using the amyloid imaging compound where an effect has been measured," said Prof. Dr. Agneta Nordberg, MD, PhD of the Karolinska Institute, "The results to date are promising and we look forward to the further analyses of the scans and spinal fluid and at the end of 6 months of treatment."

Hier die News der letzten Tage:
http://biz.yahoo.com/bw/060420/20060420005997.html?.v=1
http://biz.yahoo.com/ap/060419/axonyx_mover.html?.v=1
http://biz.yahoo.com/bw/060419/20060419005946.html?.v=1

Große Kaufe Institutioneller:
http://thomson.finance.lycos.com/lycos/iwatch/cgi-bin/iw_tic…

Der Chart schreit nach nem Ausbruch!

[Spindocter]

Überlege schon den ganzen Tag, wo ich einsteigen soll.
Denke, ich werde es zu Handelsbeginn in den US versuchen.
Großchance.

Spin

[ollinbg]

Antwort auf Beitrag Nr.: 21.270.746 von Spindocter am 21.04.06 13:40:25

Allerdings ist das ne Großchance.
Der Wert wurde dermaßen runtergeprügelt und hat es von der OTC wieder zurück an die Nasdaq geschafft.
Vor allem mit dem Hintergrund dieses Mittels gegen Alzheimer dürften hier nun auch wieder viele Fonds und Institutionelle einsteigen.

Denke der Wert hat kurz- bis mittelfristig enormes Potential!

[ollinbg]

das bid steigt in den USA jetzt schon!

Stand vor einer halben Stunde bei 1.26 und klettert im Moment auf 1.30...

Hier zu verfolgen:
http://www.pcquote.com/stocks/quote.php?symbol=axyx

[HGTPZ]

Sind aber umgerechnet nur 1,09 €!

[ollinbg]

Antwort auf Beitrag Nr.: 21.271.256 von HGTPZ am 21.04.06 14:17:05

Grade stand das bid kurz auf 1.38
Jetzt 1.32

Die ersten 6000 Stücke wurden vorbörslich schon gehandelt!

das ist heute was los

[ollinbg]

Axonyx Reports Phenserine Associated with Significant Amyloid Reduction in Phase I Trial
Tuesday February 14, 8:33 am ET
Results Support Dual Mechanisms of Action

NEW YORK--(BUSINESS WIRE)--Feb. 14, 2006--Axonyx Inc. (NASDAQ:AXYX - News) today reported a significant reduction in the plasma levels of beta-amyloid

AP
Axonyx Says Drug Safe in Study
Tuesday January 24, 9:49 am ET
Axonyx Says Alzheimer's Drug Safe and Well-Tolerated in Study, Shares Jump in Early Trading

NEW YORK (AP) -- Biotech drug developer Axonyx Inc. on Tuesday said it completed a human study of its experimental Alzheimer's treatment.
The trial found the drug, which is designed to slow progression of the mental disorder, was well-tolerated by healthy patients taking it. Patients also experienced no serious side effects,

Press Release Source: Axonyx Inc.

Axonyx Reports Statistically Significant Result for Phenserine in Alzheimer's Disease
Tuesday November 29, 8:30 am ET
Additional Analysis Results from Curtailed Phase III Clinical Trials

NEW YORK--(BUSINESS WIRE)--Nov. 29, 2005--Axonyx Inc. (NASDAQ: AXYX - News) reports today the results of an additional analysis of a subgroup of patients from its two curtailed Phase III clinical trials (AX-CL-09/010) with Phenserine, in development for mild to moderate Alzheimer's disease (AD). The subgroup of patients, who received Phenserine 15mg twice daily, demonstrated a statistically significant benefit

AP
Axonyx Licenses Alzheimer's Drug
Wednesday January 4, 9:11 am ET
Axonyx Licenses South Korean Rights to Experimental Alzheimer's Drug

NEW YORK (AP) -- Biotech drug developer Axonyx Inc. on Wednesday said it found a licensee

Posiphen, have both been found to significantly reduce beta-APP and A beta in cell culture systems and animals. As a consequence of its apparent lack of AChE inhibitory activity, Posiphen may be administered in relatively high doses. Posiphen results in meaningful reductions in A beta in Alzheimer's disease patients. No serious adverse events were reported at any dose level.

[ollinbg]

17600 Stücke vorbörslich gehandelt
Bid auf 1.38

[ollinbg]

Ask 1.50

http://finance.yahoo.com/q/ecn?s=AXYX

[Spindocter]

Antwort auf Beitrag Nr.: 21.272.055 von ollinbg am 21.04.06 15:07:31

Das lass ich mal lieber.
Da wird ein wenig übertrieben.

Spin

[ollinbg]

Antwort auf Beitrag Nr.: 21.272.192 von Spindocter am 21.04.06 15:15:22

Kommt dann nach dem ersten Schub nach Börseneröffnung eh wieder zurück.
Heute tagsüber entscheidet sich dann, wohin es geht.
Die letzte Meldung wurde gestern allerdings erst nach Börsenschluss rausgegeben. Ist denke ich mal schon noch Luft nach oben...

[ollinbg]

Und schon wieder tolle Nachrichten:

Press Release Source: Axonyx Inc.


Researcher Reports Data on Effects of Posiphen(TM) on Human Neuronal Stem Cells
Monday April 24, 8:30 am ET
Posiphen May Support Stem Cell Transplantation in Alzheimer's Disease


NEW YORK--(BUSINESS WIRE)--April 24, 2006--Axonyx Inc. (NASDAQ: AXYX - News) today announced the results of an independent study showing that Posiphen increased the ability of transplanted human neuronal stem cells (HNSC) to differentiate into neurons in APP transgenic mice, a model of Alzheimer's disease (AD) in humans. The research was reported by Kiminobu Sugaya, Ph.D., Professor of Molecular Biology, Biomolecular Sciences Center, University of Central Florida, Orlando, Florida at the 9th International Geneva/Springfield Symposium on Advances in Alzheimer's Disease held April 19 - 22, 2006 in Geneva, Switzerland.
ADVERTISEMENT


Dr. Sugaya's research showed that when APP transgenic mice had been pre-treated with Posiphen, transplanted HNSC start to differentiate into neurons in the brain area where they are needed. When HNSC were transplanted into the brains of APP transgenic mice in the absence of Posiphen, HNSC did not differentiate into neurons. Dr. Sugaya attributed this effect to Posiphen's ability to decrease the synthesis of amyloid precursor protein (APP). Posiphen may support and augment production of the new neurons through the suppression of APP production in the brain. The differentiation of stem cells into functioning neurons is critical to the success of stem cell therapy of AD.

"Although a better understanding of the mechanisms of APP function HNSC biology may be needed", stated Dr. Kiminobu Sugaya, "regulation of APP levels by a combination of Posiphen and stem cell treatments could be a promising strategy to treat AD."

About Posiphen(TM)

Posiphen is in Phase I clinical development by Axonyx for the potential treatment of AD progression and is the positive isomer of Phenserine. Posiphen treatment, similar to Phenserine, has been shown to lower secreted and cellular APP and secreted Amyloid beta (A beta) levels in neuronal cells in culture as well as in vivo studies in mice, where brain levels of both APP and A beta were significantly and dose-dependently lowered by Posiphen over a wide range of doses that were well tolerated.

About Alzheimer's Disease

Alzheimer's disease is typified by a progressive impairment in memory, cognition and emotional disturbances that result from the dysfunction and death of neurons in the brain. This pathology is considered, in part, to be the result of the over production and accumulation of beta amyloid (A beta) in and between neurons. Beta amyloid, a result of the cleavage of APP, subsequently aggregates to form plaques that are a microscopic hallmark of AD and have been postulated to have a causative role in AD.

About Axonyx

Axonyx Inc. is a U.S.-based biopharmaceutical company engaged in the acquisition and development of proprietary pharmaceutical compounds for the treatment of Central Nervous System disorders. The Company currently has three compounds in development for Alzheimer's disease; Phenserine - a potential symptomatic and disease progression treatment of mild to moderate Alzheimer's disease (AD); Posiphen(TM) - a potential disease progression treatment for AD now in Phase I; and BisNorCymcerine (BNC) - a potential symptomatic treatment of severe AD in the pre-Investigational New Drug (IND) stage.

This press release may contain forward-looking statements or predictions. These statements represent our judgment to date, and are subject to risks and uncertainties that could materially affect the Company, including those risks and uncertainties described in the documents Axonyx files from time to time with the SEC, specifically Axonyx's annual report on Form 10-K. Specifically, with respect to our drug candidates Phenserine, Posiphen(TM) and BisNorCymserine, Axonyx cannot assure that: any preclinical studies or clinical trials, whether ongoing or conducted in the future, will prove successful, and if successful, that the results can be replicated; safety and efficacy profiles of any of its drug candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; pre-clinical results related to cognition and the regulation of beta-APP and/or amyloid beta will be substantiated by ongoing or future clinical trials, if any, or that any of its drug candidates will be able to improve the signs or symptoms of their respective clinical indication or slow the progression of Alzheimer's disease; any of its drug candidates will support an NDA filing, will be approved by the FDA or its equivalent, or if approved, will prove competitive in the market; Axonyx will be able to successfully out-license any of its drug candidates; Axonyx will be able to successfully in-license any additional compounds; or that Axonyx will have or obtain the necessary financing to support its drug development programs. Axonyx cannot assure that it will be successful with regard to identifying a (sub-) licensing partner for any of its compounds. Axonyx undertakes no obligation to publicly release the result of any revisions to such forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.



Contact:
Axonyx Inc.
Colin Neill, CFO, 212-645-7704
www.axonyx.com
or
Media:
Stephanie Carrington, 646-536-7017
[e-mail]

[ollinbg]

Dazu 9 neue Research Reports seit Freitag!

http://finance.yahoo.com/q/rr?s=AXYX

[ollinbg]

Noch zur Info:
Die haben eine Menge Cash und eine 31%ige Beteiligung an Oxis.
Alleine das bedeutet einen Wert des Unternehmens von 1.20 $ pro Aktie!

Dazu kommt jetzt noch die Phantasie der aktuellen Meldungen.
Die Aktie kam von über 8$ und wurde wenn ich das richtig gelesen habe wegen einem schlechten PhaseIII Ergebnis runtergeprügelt.

Da ist also noch eine Menge Luft nach oben!

[ODI01]

04.10.2006 14:10
TorreyPines Therapeutics Completes Merger With Axonyx

LA JOLLA, Calif., Oct. 4 /PRNewswire-FirstCall/ -- TorreyPines Therapeutics, (Nachrichten) Inc. today announced the completion of its merger with Axonyx Inc. The combined company will operate as TorreyPines Therapeutics, Inc. under the leadership of TorreyPines' management team. TorreyPines begins trading today on the NASDAQ Global Market under the ticker symbol "TPTX."

The merger creates a publicly traded biopharmaceutical company that discovers and develops treatments for diseases and disorders of the central nervous system (CNS). TorreyPines' initial focus is on migraine and cognitive disorders.

"This merger is consistent with our objective to maximize shareholder value," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines. "We now have a strong pipeline of eight product candidates, five of which are clinical stage, with our lead compound, tezampanel, to begin a Phase IIb study for acute migraine by the end of the year. We look forward to strategically advancing our product candidates for migraine and cognitive disorders while prudently managing our resources."

In connection with the merger, Axonyx effected a 1-for-8 reverse stock split of its common stock. As a result of the merger and the reverse stock split, the combined company has approximately 15.7 million shares issued and outstanding. TorreyPines stockholders own approximately 58 percent of the combined company and Axonyx stockholders own approximately 42 percent.

"The completion of this merger helps to position TorreyPines as a premier biopharmaceutical company focused on CNS diseases and disorders," said Jean Deleage, Managing Partner of venture firm Alta Partners and Chairman of the Board of Directors of TorreyPines. "The company has a management team with a successful clinical development track record, a healthy balance sheet, a robust portfolio of clinical candidates and promising discovery research. This is an exciting time for TorreyPines and its shareholders."

In connection with the closing, the company's Board of Directors will number ten, including directors from both TorreyPines and Axonyx.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a biopharmaceutical company that discovers and develops small molecule drugs to treat diseases and disorders of the central nervous system. Led by an accomplished management team, TorreyPines is leveraging novel drug targets and technologies to potentially deliver new CNS therapies for migraine; chronic pain, including neuropathic pain; and cognitive disorders, including Alzheimer's disease and schizophrenia. Further information is available at http://www.torreypinestherapeutics.com/.

This press release contains forward-looking statements or predictions. Such forward-looking statements include statements regarding the expected benefits of the merger of TorreyPines Therapeutics and Axonyx for stockholders of the combined company, expectations regarding advancement of the company's product candidates and management of the company's resources, and the potential of the company's product candidates to treat certain diseases and disorders. Such statements are subject to numerous factors, risks, and uncertainties that may cause actual events or results to differ materially from the combined company's current expectations. Actual results may differ materially from the above forward-looking statements due to a number of important factors including that TorreyPines Therapeutics may not be able to execute its integration strategies or realize the expected benefits of the merger. Statements regarding TorreyPines Therapeutics' product candidates are subject to risks and uncertainties regarding development, regulatory approval and commercialization, including whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of its drug candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of its drug candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of its drug candidates will support an NDA filing, will be approved by the FDA or its equivalent, or if approved, will prove competitive in the market; or whether the necessary financing to support its drug development programs will be available. These and other risks which may impact management's expectations are described in greater detail in the registration statement on Form S-4, as amended, as filed with the Securities and Exchange Commission and Axonyx's other SEC reports. TorreyPines Therapeutics undertakes no obligation to publicly release the result of any revisions to such forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.





Klicken Sie hier, um weitere aktuelle Nachrichten zum Unternehmen zu finden:

TORREYPINES THERAPEUTICS